International Journal of Hematology

, Volume 87, Issue 4, pp 434–439 | Cite as

Virus reactivation in high-risk non-Hodgkin’s lymphoma patients after autologous CD34+-selected peripheral blood progenitor cell transplantation

  • Peng-Chan Lin
  • Ming-Yang Lee
  • Jen-Tsun Lin
  • Liang-Tsai Hsiao
  • Po-Min Chen
  • Tzeon-Jye Chiou
Case Report


CD34+-selected peripheral blood progenitor cells (PBPCs) may not only reduce contaminated tumor cells but also compromise immunologic reconstitution and increase incidence of infections after transplantation. We analyzed the incidence of virus reactivation in CD34+-selected PBPCs autologous transplantation. From December 2001 to December 2004, ten high-risk aggressive non-Hodgkin’s lymphoma (NHL) patients were enrolled in a program of high-dose chemotherapy plus autologous CD34+-selected PBPCs support. Viral screening studies, including clinical symptoms, physical examinations, hepatitis B virus (HBV)-DNA, cytomegalovirus (CMV)-polymerase chain reaction (PCR), rapid diagnosis of fluorescent antibody stain for herpes-simplex virus (HSV), and viral culture from blood, fluid or tissue were performed weekly during the first 3 months and then monthly for 1 year. Two of four patients (50%) who were HBV carriers developed HBV reactivation. The other two HBV carriers who received prophylactic lamivudine therapy did not develop HBV reactivation. Two patients (20%) developed cytomegalovirus (CMV) infection, and three patients (30%) developed HSV infection in total ten serum-positive patients. The possibility of virus reactivation might increase in NHL patients undergoing autologous CD34+-selected PBPC transplantation. Administering prophylactic antivirus therapy and closely following patient’s clinical viral complications should be considered.


CD34+-selected PBPCs Virus reactivation Non-Hodgkin’s lymphoma Autotransplantation 



We greatly thank the grant supports from Taiwan Clinical Cancer Research Foundation, Taipei, Taiwan and Taipei Veterans General Hospital in this study.


  1. 1.
    Shipp MA, Yeap BY, Harrington DP, et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol. 1990;8:84–93.PubMedGoogle Scholar
  2. 2.
    Coiffier B, Gisselbrecht C, Herbrecht R, et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989;7:1018–26.PubMedGoogle Scholar
  3. 3.
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5.PubMedCrossRefGoogle Scholar
  5. 5.
    A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987–94.CrossRefGoogle Scholar
  6. 6.
    Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin’s lymphoma in first complete remission: a study of 464 patients. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1994;12:2543–51.PubMedGoogle Scholar
  7. 7.
    Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87–2. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 1997;15:1131–7.PubMedGoogle Scholar
  8. 8.
    Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:2796–802.PubMedGoogle Scholar
  10. 10.
    Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet. 1993;341:85–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Mori M, Mimori K, Inoue H, et al. Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res. 1995;55:3417–20.PubMedGoogle Scholar
  12. 12.
    Nachbaur D, Fink FM, Nussbaumer W, et al. CD34+-selected autologous peripheral blood stem cell transplantation (PBSCT) in patients with poor-risk hematological malignancies and solid tumors. A single-centre experience. Bone Marrow Transplant. 1997;20:827–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Miyamoto T, Gondo H, Miyoshi Y, et al. Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin’s lymphoma. Br J Haematol. 1998;100:348–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood. 1999;94:4029–35.PubMedGoogle Scholar
  15. 15.
    Crippa F, Holmberg L, Carter RA, et al. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:281–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Frere P, Pereira M, Fillet G, et al. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. Eur J Haematol. 2006;76:102–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Goldschmidt H, Hegenbart U, Haas R, et al. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant. 1996;17:691–7.PubMedGoogle Scholar
  18. 18.
    Philip T, Chauvin F, Armitage J, et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991;77:1587–92.PubMedGoogle Scholar
  19. 19.
    Imai Y, Chou T, Tobinai K, et al. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin’s lymphoma (NHL): results of Japanese phase II study. Bone Marrow Transplant. 2005;35:479–87.PubMedCrossRefGoogle Scholar
  20. 20.
    Despres D, Flohr T, Uppenkamp M, et al. CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device. J Hematother Stem Cell Res. 2000;9:557–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Ringhoffer M, Wiesneth M, Harsdorf S, et al. CD34 cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. Br J Haematol. 2004;126:527–35.PubMedCrossRefGoogle Scholar
  22. 22.
    Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99:2324–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Lin PC, Poh SB, Lee MY, et al. Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients. Int J Hematol. 2005;81:349–51.PubMedCrossRefGoogle Scholar
  24. 24.
    Hsiao LT, Chiou TJ, Liu JH, et al. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;12:84–94.PubMedCrossRefGoogle Scholar
  25. 25.
    Takeshima M, Takamatsu H, Iida M, et al. Frequent viral infections and delayed CD4+ cell recovery following CD34+ cell-selected autologous peripheral blood stem cell transplantation. Int J Hematol. 1999;70:193–9.PubMedGoogle Scholar
  26. 26.
    Reusser P, Attenhofer R, Hebart H, et al. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood. 1997;89:3873–9.PubMedGoogle Scholar
  27. 27.
    Teshima T, Harada M, Takamatsu Y, et al. Cytotoxic drug and cytotoxic drug/G-CSF mobilization of peripheral blood stem cells and their use for autografting. Bone Marrow Transplant. 1992;10:215–20.PubMedGoogle Scholar
  28. 28.
    Hertenstein B, Hampl W, Bunjes D, et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant. 1995;15:387–93.PubMedGoogle Scholar
  29. 29.
    Landais E, Saulquin X, Houssaint E. The human T cell immune response to Epstein–Barr virus. Int J Dev Biol. 2005;49:285–292.PubMedCrossRefGoogle Scholar
  30. 30.
    Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110(7):2316–23. Epub 2007.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2008

Authors and Affiliations

  • Peng-Chan Lin
    • 1
    • 2
  • Ming-Yang Lee
    • 1
  • Jen-Tsun Lin
    • 1
  • Liang-Tsai Hsiao
    • 1
  • Po-Min Chen
    • 1
  • Tzeon-Jye Chiou
    • 1
    • 3
  1. 1.Division of Hematology and Oncology, Department of MedicineTaipei Veterans General Hospital and National Yang-Ming University School of MedicineTaipeiTaiwan
  2. 2.Division of Hematology and Oncology, Department of MedicineNational Cheng Kung University HospitalTainanTaiwan
  3. 3.Division of Transfusion Medicine, Department of MedicineTaipei Veterans General Hospital and National Yang-Ming University School of MedicineTaipeiTaiwan

Personalised recommendations